The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., & Smith, R. L. (1980) · Journal of Medical Genetics · doi:10.1136/jmg.17.2.102 · Cited by 536
Ethnic Differences in Drug Metabolism
Kalow, W. (1982) · Clinical Pharmacokinetics · doi:10.2165/00003088-198207050-00001 · Cited by 220
Pharmacogenetics of Tolbutamide Metabolism in Humans
Scott, J., & Poffenbarger, P. L. (1978) · Diabetes · doi:10.2337/diab.28.1.41 · Cited by 179
Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance
Idle, J. R., & Smith, R. L. (1979) · Drug Metabolism Reviews · doi:10.3109/03602537908993896 · Cited by 164
Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution
Nebert, D. W., & Negishi, M. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90523-8 · Cited by 144
Nebert, D. W. (1979) · Molecular and Cellular Biochemistry · doi:10.1007/bf00849277 · Cited by 142
Pharmacogenetics of tolbutamide metabolism in humans
Scott, J., & Pl, P. (1979) · Diabetes · doi:10.2337/diabetes.28.1.41 · Cited by 139
Stereoselective metabolism of mephenytoin in man.
Kupfer, A., Roberts, R. K., Schenker, S., et al. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32651-0 · Cited by 76
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., & Waxman, D. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89213-x · Cited by 724
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Molecular genetics of the P-450 superfamily
Gonzalez, F. J. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90006-n · Cited by 493
Ishizaki, & Horai (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00022.x · Cited by 428
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
Meyer, U. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1428 · Cited by 420
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Purification and characterization of hepatic microsomal cytochrome P-450
Ryan, D. E., & Levin, W. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90029-2 · Cited by 377
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Tate, S. K., Depondt, C., Sisodiya, S. M., Cavalleri, G. L., Schorge, S., Soranzo, N., Thom, M., Sen, A., Shorvon, S. D., Sander, J. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407346102 · Cited by 345
Genetic polymorphism of S-mephenytoin hydroxylation
Wilkinson, G. R., Peter Guengerich, F., & Branch, R. A. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90047-8 · Cited by 292
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Hasler, J. A., Estabrook, R., Murray, M., Pikuleva, I., Waterman, M., Capdevila, J., Holla, V., Helvig, C., Falck, J. R., Farrell, G., et al. (1999) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(99)00005-9 · Cited by 267
Wedlund, P. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R., & Branch, R. A. (1984) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1984.256 · Cited by 263
Shimada, T., Misono, K. S., & Guengerich, F. P. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36183-5 · Cited by 256
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241
Identification of Human Liver Cytochrome P450 Isoforms Mediating Omeprazole Metabolism
ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A., & BIRKETT, D. J. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00410.x · Cited by 230
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
General Principles of Pharmacokinetics
Preskorn, S. H., & Catterson, M. L. (2004) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-18500-7_2 · Cited by 14
Metadata
- Authors
- K�pfer, A., & Preisig, R.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1984
- Volume
- 26
- Issue
- 6
- Pages
- 753-759
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W1991163272
- Cited by
- 362
- References
- 14
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.